MA47106A - Formulations d'anticorps anti-tnf alpha - Google Patents

Formulations d'anticorps anti-tnf alpha

Info

Publication number
MA47106A
MA47106A MA047106A MA47106A MA47106A MA 47106 A MA47106 A MA 47106A MA 047106 A MA047106 A MA 047106A MA 47106 A MA47106 A MA 47106A MA 47106 A MA47106 A MA 47106A
Authority
MA
Morocco
Prior art keywords
tnf alpha
antibody formulations
alpha antibody
formulations
tnf
Prior art date
Application number
MA047106A
Other languages
English (en)
Inventor
Joy Brennan
William J Callahan
Rahul Rajan Kaushik
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MA47106A publication Critical patent/MA47106A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA047106A 2016-12-21 2017-12-20 Formulations d'anticorps anti-tnf alpha MA47106A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662437640P 2016-12-21 2016-12-21

Publications (1)

Publication Number Publication Date
MA47106A true MA47106A (fr) 2019-10-30

Family

ID=61006357

Family Applications (1)

Application Number Title Priority Date Filing Date
MA047106A MA47106A (fr) 2016-12-21 2017-12-20 Formulations d'anticorps anti-tnf alpha

Country Status (4)

Country Link
US (3) US20200087390A1 (fr)
EP (3) EP3558363A1 (fr)
MA (1) MA47106A (fr)
WO (1) WO2018119142A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200087390A1 (en) 2016-12-21 2020-03-19 Amgen Inc. Anti-tnf alpha antibody formulations
TW202108171A (zh) * 2019-04-23 2021-03-01 法商賽諾菲公司 穩定的低黏度抗體調配物及其用途
US11655302B2 (en) 2019-06-10 2023-05-23 Sanofi Anti-CD38 antibodies and formulations
IL310275A (en) * 2021-08-12 2024-03-01 Amgen Inc Antibody formulations

Family Cites Families (669)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5945098A (en) 1990-02-01 1999-08-31 Baxter International Inc. Stable intravenously-administrable immune globulin preparation
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US7192584B2 (en) 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US5698195A (en) 1991-03-18 1997-12-16 New York University Medical Center Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies
US5919452A (en) 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
US5656272A (en) 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
US6270766B1 (en) 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
KR100388569B1 (ko) 1994-04-22 2003-10-11 야마노우치세이야쿠 가부시키가이샤 결장특이적약물방출용경구약제학적제제
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
HU230048B1 (hu) 1996-02-09 2015-06-29 Abbvie Biotechnology Ltd Humán TNFalfa-kötő antitestek alkalmazása
GB9610992D0 (en) 1996-05-24 1996-07-31 Glaxo Group Ltd Concentrated antibody preparation
EP0938334A4 (fr) 1996-07-26 2004-12-15 Smithkline Beecham Corp Methode amelioree de traitement de maladies de l'organisme induites par des cellules immunes
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
DK0917879T3 (da) 1997-11-22 2002-11-04 Roche Diagnostics Gmbh Forbedret fremgangsmåde til stabilisering af proteiner
AU742250B2 (en) 1997-12-26 2001-12-20 Astellas Pharma Inc. Sustained release medicinal compositions
DE19814084B4 (de) 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
JP4685238B2 (ja) 1998-06-09 2011-05-18 ツエー・エス・エル・ベーリング・アクチエンゲゼルシヤフト 静脈投与用免疫グロブリン及び他の免疫グロブリン生成物の製造法
GB9812545D0 (en) 1998-06-10 1998-08-05 Celltech Therapeutics Ltd Biological products
DE69922009T2 (de) 1998-07-23 2005-04-07 Fujisawa Pharmaceutical Co., Ltd. Imidazolverbindungen und ihre verwendung als adenosindeaminase-inhibitoren
GB9824632D0 (en) 1998-11-10 1999-01-06 Celltech Therapeutics Ltd Biological compounds
ATE331730T1 (de) 1999-01-13 2006-07-15 Astellas Pharma Inc Neue depsipeptid-verbindung
EP2168984B1 (fr) 1999-03-25 2012-08-29 Abbott GmbH & Co. KG Anticorps humains qui se lient au IL-12 humain et procédé de fabrication
US6716613B1 (en) 1999-11-11 2004-04-06 Yamanouchi Pharmaceutical Co., Ltd. Metalloprotease having aggrecanase activity
EP1240313B1 (fr) 1999-12-22 2006-07-26 Ucb, S.A. Enzymes homologues de l'heparanase humaine et variants d'epissage
KR100740761B1 (ko) 2000-02-25 2007-07-19 옥스포드 글리코사이언시스(유케이) 리미티드 단백질
DE60130910T2 (de) 2000-04-17 2008-07-10 Ucb Pharma, S.A. Enamin-derivate als zell-adhäsionsmoleküle
JP2001322933A (ja) 2000-05-15 2001-11-20 Ucb Sa Ｃｄ４０シグナル遮断剤
GB0013810D0 (en) 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
ATE368735T1 (de) 2000-12-18 2007-08-15 Astellas Pharma Inc Neue aggrecanase
WO2002053544A1 (fr) 2000-12-29 2002-07-11 Darwin Discovery Ltd. Utilisations pharmaceutiques et synthese de nicotinanilide-n-oxydes
CA2817619A1 (fr) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methodes pour administrer des anticorps anti-tnf.alpha.
GB0114644D0 (en) 2001-06-15 2001-08-08 Oxford Glycosciences Uk Ltd Protein
ATE417038T1 (de) 2001-06-15 2008-12-15 Astellas Pharma Inc Phenylpyridincarbonyl piperazinderivate
CA2451955C (fr) 2001-06-26 2015-09-29 Abgenix, Inc. Anticorps opgl
WO2003009740A2 (fr) 2001-07-24 2003-02-06 Biogen Idec Ma Inc. Methodes de traitement ou de prevention de troubles sclereux par l'usage d'agents se liant a cd2
TWI327597B (en) 2001-08-01 2010-07-21 Centocor Inc Anti-tnf antibodies, compositions, methods and uses
JP2005500847A (ja) 2001-08-24 2005-01-13 アドバンスド セル テクノロジー、インコーポレイテッド 分化誘導薬の同定のためのスクリーニング検定及び細胞治療用の分化細胞の調製
BR0213078A (pt) 2001-09-25 2004-11-23 Fujisawa Pharmaceutical Co Anticorpo recombinante anti-osteopontina e uso do mesmo
ES2392073T3 (es) 2001-11-08 2012-12-04 Abbott Biotherapeutics Corp. Formulación farmacéutica líquida estable de anticuerpos IGG
US20050118656A1 (en) 2001-11-27 2005-06-02 Terrett Jonathan A. Methods for diagnosis and treatment of epithelial-derived cancers
US7261892B2 (en) 2001-11-27 2007-08-28 Celltech R&D Limited Methods for diagnosis and treatment of epithelial-derived cancers
GB0129105D0 (en) 2001-12-05 2002-01-23 Celltech R&D Ltd Expression control using variable intergenic sequences
GB0207533D0 (en) 2002-04-02 2002-05-08 Oxford Glycosciences Uk Ltd Protein
GB0208089D0 (en) 2002-04-09 2002-05-22 Oxford Glycosciences Uk Ltd Protein
CN101200450A (zh) 2002-04-30 2008-06-18 Ucb公司 2,6-喹啉基和2,6-萘基衍生物、用于制备它们的方法和它们作为vla-4抑制剂的用途
AU2003240790A1 (en) 2002-05-28 2003-12-12 Pharmacia Corporation Antibody peg positional isomers, compositions comprising same, and use thereof
CA2480619A1 (fr) 2002-06-06 2003-12-18 Masakatsu Kawakami Nouvelle oxydase
GB0214268D0 (en) 2002-06-20 2002-07-31 Celltech R&D Ltd Chemical compounds
EP1521581B1 (fr) 2002-07-02 2008-02-20 UCB Farchim S.A. Diarylmethylpiperazines utiles comme agents prophylactiques ou therapeutiques de la myocardite virale
PL218992B1 (pl) 2002-07-19 2015-02-27 Abbott Biotech Ltd Neutralizujące o wysokim powinowactwie izolowane ludzkie przeciwciało anty-TNFα, zastosowanie tego przeciwciała, kryształ zawierający ludzkie przeciwciało anty-TNFα i preparat zawierający ten kryształ
GB0218800D0 (en) 2002-08-13 2002-09-18 Celltech R&D Ltd Chemical compounds
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
GB0222743D0 (en) 2002-10-01 2002-11-06 Celltech R&D Ltd Chemical compounds
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
EP2258724A1 (fr) 2002-11-21 2010-12-08 Celltech R & D, Inc. Modulation de réponses immunitaires utilisant des anticorps anti-CD83 multimerisés
US9498530B2 (en) 2002-12-24 2016-11-22 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
NZ541232A (en) 2003-01-09 2008-02-29 Astellas Pharma Inc Pyrrolopyridazine derivatives
CA2513660C (fr) 2003-01-23 2012-05-08 Esperion Therapeutics, Inc. Composes hydroxyles et compositions de regulation du cholesterol et utilisations associees
US20040230309A1 (en) 2003-02-14 2004-11-18 Depuy Spine, Inc. In-situ formed intervertebral fusion device and method
EP1595952A4 (fr) 2003-02-19 2008-05-21 Astellas Pharma Inc Procede d'evaluation de l'effet antitumoral d'un inhibiteur d'histone desacetylase
US6805686B1 (en) 2003-05-06 2004-10-19 Abbott Laboratories Autoinjector with extendable needle protector shroud
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
EP1481683A1 (fr) 2003-05-30 2004-12-01 Yamanouchi Pharmaceutical Co. Ltd. Ligands ayant pour cible la P-selectine et compositions les comprenant
EP1641804A1 (fr) 2003-06-20 2006-04-05 Celltech R & D Limited Derives de thienopyridone en tant qu inhibiteurs de kinase
JP2007516162A (ja) 2003-06-20 2007-06-21 セルテック アール アンド ディ リミテッド キナーゼ阻害剤としてのチエノピリドン誘導体
EP1640010A1 (fr) 2003-07-01 2006-03-29 Astellas Pharma Inc. Agent d'induction de croissance dans la masse osseuse
HUE026278T2 (en) 2003-07-01 2016-05-30 Ucb Biopharma Sprl Modified Fab antibody fragments
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
EP1680429A1 (fr) 2003-10-24 2006-07-19 Celltech R & D Limited Utilisation de derives de thieno-pyridonone comme inhibiteurs de kinases
GB0325836D0 (en) 2003-11-05 2003-12-10 Celltech R&D Ltd Biological products
PT1685849E (pt) 2003-11-20 2012-02-15 Astellas Pharma Inc Inibidores de pde4 para o tratamento da cistite intersticial
SI1983000T1 (sl) 2003-11-21 2015-12-31 Ucb Biopharma Sprl Postopek za zdravljenje multiple skleroze z zaviranjem aktivnosti il-17
MX370489B (es) 2004-01-09 2019-12-16 Pfizer Anticuerpos contra madcam.
JP2007104901A (ja) 2004-01-16 2007-04-26 Astellas Pharma Inc 関節リウマチ治療薬のスクリーニング法
JP2007104902A (ja) 2004-01-16 2007-04-26 Astellas Pharma Inc 関節リウマチ治療薬のスクリーニング法
US20190282622A1 (en) 2004-01-23 2019-09-19 Astellas Institute For Regenerative Medicine Modalities for the treatment of degenerative diseases of the retina
US7670624B2 (en) 2004-01-29 2010-03-02 Astella Pharma Inc. Gastrointestinal-specific multiple drug release system
TWI439284B (zh) 2004-04-09 2014-06-01 艾伯維生物技術有限責任公司 用於治療ＴＮＦα相關失調症之多重可變劑量療法
MXPA06011827A (es) 2004-04-15 2007-01-16 Astellas Pharma Inc Derivado de 2-aminopirimidina.
GB0411186D0 (en) 2004-05-19 2004-06-23 Celltech R&D Ltd Biological products
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
JP2007269629A (ja) 2004-06-21 2007-10-18 Astellas Pharma Inc キナゾリン誘導体
JP2007277093A (ja) 2004-06-21 2007-10-25 Astellas Pharma Inc 三環系化合物
GB0414054D0 (en) 2004-06-23 2004-07-28 Owen Mumford Ltd Improvements relating to automatic injection devices
JP5092402B2 (ja) 2004-07-05 2012-12-05 アステラス製薬株式会社 ピラゾロピリジン誘導体
WO2006004191A1 (fr) 2004-07-05 2006-01-12 Astellas Pharma Inc. Derivés de pyrrolopyridazine qui inhibent la pde iv et le tnf alpha
WO2006038734A1 (fr) 2004-10-08 2006-04-13 Astellas Pharma Inc. Dérivés de la pyridazinone inhibiteurs de cytokines
US7893315B2 (en) 2004-11-04 2011-02-22 Advanced Cell Technology, Inc. Derivation of embryonic stem cells and embryo-derived cells
GB0425569D0 (en) 2004-11-19 2004-12-22 Celltech R&D Ltd Biological products
GB0425972D0 (en) 2004-11-25 2004-12-29 Celltech R&D Ltd Biological products
EA016022B1 (ru) 2004-12-21 2012-01-30 Сентокор, Инк. Выделенное антитело млекопитающего против il-12 и способ изменения его активности
US20090012499A1 (en) 2005-02-08 2009-01-08 Japan As Rep. By Pres. Of Nat. Cardiovascular Ctr. Novel method for treating chronic severe heart failure by using insulin-like growth factor-1 (igf-1)
EP1854484A4 (fr) 2005-02-16 2010-02-10 Astellas Pharma Inc Remède contre la douleur contenant un inhibiteur de la protéine rho-kinase
GB0506912D0 (en) 2005-04-05 2005-05-11 Celltech R&D Ltd Biological products
KR101465456B1 (ko) 2005-05-16 2014-11-27 애브비 바이오테크놀로지 리미티드 미란성 다발관절염의 치료를 위한 ｔｎｆ 억제제의 용도
DE602006019731D1 (de) 2005-06-09 2011-03-03 Ucb Pharma Sa 2,6-chinolinderivate sowie verfahren zu ihrer herstellung und verwendung als arzneimittel
WO2006138181A2 (fr) 2005-06-14 2006-12-28 Amgen Inc. Preparations de proteines a tamponnage spontane
EP2452694B1 (fr) 2005-06-30 2018-11-14 Janssen Biotech, Inc. Anticorps anti-IL-23, compositions, procédés et utilisations
GB0513852D0 (en) 2005-07-06 2005-08-10 Celltech R&D Ltd Biological products
GB0514779D0 (en) 2005-07-19 2005-08-24 Celltech R&D Ltd Biological products
CA2659945C (fr) 2005-08-03 2014-12-16 Advanced Cell Technology, Inc. Procedes ameliores de reprogrammation de cellules somatiques animales
JP4992716B2 (ja) 2005-08-12 2012-08-08 アステラス製薬株式会社 薬剤の標的蛋白質を同定する方法及び標的蛋白質を用いた糖尿病治療薬のスクリーニング方法
EP1754476A1 (fr) 2005-08-18 2007-02-21 Schwarz Pharma Ag Lacosamide (SPM 927) pour le traitement de la myalgie, par exemple de la fibromyalgie
KR20080049758A (ko) 2005-09-01 2008-06-04 아스텔라스세이야쿠 가부시키가이샤 통증 치료용으로 사용되는 피리다지논 유도체
AU2006290567A1 (en) 2005-09-14 2007-03-22 Ucb Pharma S.A Comb polymers
GB0520169D0 (en) 2005-10-04 2005-11-09 Celltech R&D Ltd Biological products
PT1948235E (pt) 2005-11-01 2013-11-26 Abbvie Biotechnology Ltd Métodos de determinação da eficácia de adalimumab em sujeitos com espondilite anquilosante, utilizando ctx-ii e mmp3 como biomarcadores
GB0523954D0 (en) 2005-11-24 2006-01-04 Ucb Celltech Bioassays
EP1790664A1 (fr) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Anticorps monoclonaux contre claudin-18 pour le traitement du cancer
WO2007060411A1 (fr) 2005-11-24 2007-05-31 Ucb Pharma S.A. Anticorps anti-tnf alpha qui inhibent sélectivement le signal tnf alpha par le p55r
CN101356194B (zh) 2005-12-09 2013-06-12 Ucb医药有限公司 对人il-6具有特异性的抗体分子
EP2738179A1 (fr) 2006-04-05 2014-06-04 AbbVie Biotechnology Ltd Purification d'anticorps
EP2012586A4 (fr) 2006-04-10 2010-08-18 Abbott Biotech Ltd Utilisations et compositions pour le traitement de la spondylarthrite ankylosante
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
WO2007120656A2 (fr) 2006-04-10 2007-10-25 Abbott Biotechnology Ltd. Utilisations et compositions pour le traitement de la polyarthrite rhumatoïde
EP2666472A3 (fr) 2006-04-10 2014-04-02 Abbott Biotechnology Ltd Utilisations et compositions pour le traitement de l'arthrite psoriasique
KR102651433B1 (ko) 2006-04-14 2024-03-25 아스텔라스 인스티튜트 포 리제너러티브 메디슨 혈관 콜로니 형성 세포
US8808707B1 (en) 2006-05-08 2014-08-19 Wyeth Llc Pneumococcal dosing regimen
TW200813087A (en) 2006-05-31 2008-03-16 Astellas Pharma Inc Humanized anti-human osteopontin antibody
US20100021451A1 (en) 2006-06-08 2010-01-28 Wong Robert L Uses and compositions for treatment of ankylosing spondylitis
AU2007256352A1 (en) 2006-06-08 2007-12-13 Ucb Pharma Gmbh Therapeutic combination for painful medical conditions
TWI392670B (zh) 2006-06-22 2013-04-11 Ucb Pharma Gmbh 經取代的２-胺基萘滿之於製造用於預防、減緩及／或治療各種類型疼痛之藥物上的用途
GB0612928D0 (en) 2006-06-29 2006-08-09 Ucb Sa Biological products
TWI498137B (zh) 2006-06-30 2015-09-01 Abbvie Biotechnology Ltd 自動注射裝置
GB0613209D0 (en) 2006-07-03 2006-08-09 Ucb Sa Methods
EP2046739B1 (fr) 2006-07-24 2015-08-26 UCB Biopharma SPRL Dérivés d'aniline substitués
GB0614780D0 (en) 2006-07-25 2006-09-06 Ucb Sa Biological products
SG174013A1 (en) 2006-07-27 2011-09-29 Wyeth Corp High-cell density fed-batch fermentation process for producing recombinant protein
US20090317455A1 (en) 2006-08-31 2009-12-24 Naoto Oku Reverse targeting lipid vesicle
US20100035863A1 (en) 2006-09-12 2010-02-11 Ucb Pharma, S.A. 2 Amino-Pyrimidine Derivatives As H4 Receptor Antagonists, Processes For Preparing Them And Their Use In Pharmaceutical Compositions
MX353340B (es) 2006-09-13 2018-01-09 Abbvie Inc Mejoras de cultivos celulares.
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
CN101517082B (zh) 2006-09-27 2014-01-22 科勒制药有限责任公司 具有增强的免疫刺激活性的含疏水性T类似物的CpG寡聚核苷酸类似物
GB0619291D0 (en) 2006-09-29 2006-11-08 Ucb Sa Altered antibodies
US10068220B2 (en) 2006-10-11 2018-09-04 Visa International Service Association Systems and methods for brokered authentication express seller links
GB0620729D0 (en) 2006-10-18 2006-11-29 Ucb Sa Biological products
NZ613356A (en) 2006-10-27 2015-02-27 Abbvie Biotechnology Ltd Crystalline anti-htnfalpha antibodies
WO2008064830A1 (fr) 2006-11-27 2008-06-05 Ucb Pharma, S.A. Dérivés bicycliques et hétérobicycliques, leurs procédés de fabrication et leurs utilisations pharmaceutiques
WO2008064823A1 (fr) 2006-11-27 2008-06-05 Ucb Pharma, S.A. Dérivés bicycliques et hétérobicycliques, procédés de préparation de ceux-ci et leurs utilisations
US20100179185A1 (en) 2006-11-30 2010-07-15 Ucb Pharma, S.A. Novel Aminothienopyridinone Derivatives Processes for Preparing Them and Pharmaceutical Compositions Thereof
WO2008074445A1 (fr) 2006-12-18 2008-06-26 Ucb Pharma, S.A. Nouveaux dérivés tricycliques et hétérocycliques, procédés destinés à les préparer et compositions pharmaceutiques les contenant
US8540992B2 (en) 2006-12-28 2013-09-24 Michael Naso Methods and vectors for generating asialylated immunoglobulins
US20090022727A1 (en) 2007-01-26 2009-01-22 Alza Corp. Injectable, nonaqueous suspension with high concentration of therapeutic agent
US8147833B2 (en) 2007-02-23 2012-04-03 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
WO2008103462A2 (fr) 2007-02-23 2008-08-28 Advanced Cell Technology, Inc. Procédés hautement efficaces pour reprogrammer des cellules différenciées et pour produire des animaux et des cellules souches embryonnaires à partir de cellules reprogrammées
SG196697A1 (en) 2007-03-22 2014-02-13 Biogen Idec Inc Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 and uses thereof
WO2008121324A2 (fr) 2007-03-30 2008-10-09 Abbott Laboratories Eléments de vecteurs d'expression recombinants (reve) destinés à augmenter l'expression de protéines recombinantes dans des cellules hôtes
WO2008122378A1 (fr) 2007-04-04 2008-10-16 Ucb Pharma, S.A. Nouveaux derives de pyridine, procedes de preparation et compositions pharmaceutiques associes
WO2008125215A1 (fr) 2007-04-12 2008-10-23 Ucb Pharma, S.A. Dérivés bicycliques et hétérobicycliques, procédés de préparation et utilisations de ceux-ci
WO2008125210A1 (fr) 2007-04-12 2008-10-23 Ucb Pharma, S.A. Dérivés de quinoline et de naphtalène, procédés de préparation et utilisation de ceux-ci pour traiter des maladies inflammatoires
TW200904421A (en) 2007-05-03 2009-02-01 Astellas Pharma Inc New compounds
WO2008138592A1 (fr) 2007-05-14 2008-11-20 Ucb Pharma, S.A. Dérivés bicycliques et hétérobicycliques, leurs méthodes de préparation et leurs utilisations
WO2008138591A2 (fr) 2007-05-14 2008-11-20 Ucb Pharma, S.A. Dérivés bicycliques et hétérobicycliques, leurs méthodes de préparation et leurs utilisations
WO2008138615A1 (fr) 2007-05-16 2008-11-20 Ucb Pharma, S.A. Dérivés bicycliques et hétérobicycliques, leurs méthodes de préparation et leurs utilisations
EP1997832A1 (fr) 2007-05-29 2008-12-03 Ganymed Pharmaceuticals AG Anticorps monoclonaux contre la claudine-18 pour le traitement contre le cancer
US8092998B2 (en) 2007-05-31 2012-01-10 Abbott Laboratories Biomarkers predictive of the responsiveness to TNFα inhibitors in autoimmune disorders
EP2154130A4 (fr) 2007-06-07 2011-09-07 Astellas Pharma Inc Composé de pyridone
MX2009013410A (es) 2007-06-08 2010-03-22 Biogen Idec Inc Biomarcadores para predecir capacidad de respuesta anti-tnf o sin capacidad de respuesta.
US8999337B2 (en) 2007-06-11 2015-04-07 Abbvie Biotechnology Ltd. Methods for treating juvenile idiopathic arthritis by inhibition of TNFα
WO2009020654A1 (fr) 2007-08-08 2009-02-12 Abbott Laboratories Compositions et procédés permettant la cristallisation d'anticorps
CA2696210A1 (fr) 2007-08-28 2009-03-12 Abbott Biotechnology Ltd. Compositions et procedes comprenant des proteines de liaison pour adalimumab
US8629246B2 (en) 2007-09-26 2014-01-14 Ucb Pharma S.A. Dual specificity antibody fusions
US20100298289A1 (en) 2007-10-09 2010-11-25 Ucb Pharma, S.A. Heterobicyclic compounds as histamine h4-receptor antagonists
CN104946591A (zh) 2007-10-12 2015-09-30 奥卡塔治疗公司 制备rpe 细胞和rpe 细胞的组合物的改良方法
PT2222697E (pt) 2007-11-01 2013-02-15 Perseid Therapeutics Llc Polipeptídeos imunossupressores e ácidos nucleicos
WO2009059235A2 (fr) 2007-11-01 2009-05-07 Facet Biotech Corporation Vecteurs de présentation d'immunoglobulines
KR20210049186A (ko) 2007-11-30 2021-05-04 애브비 바이오테크놀로지 리미티드 단백질 제형 및 이의 제조방법
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
KR101577843B1 (ko) 2007-12-14 2015-12-16 브리스톨-마이어스 스큅 컴퍼니 인간 ｏｘ４０ 수용체에 대한 결합 분자
BRPI0906490A2 (pt) 2008-01-15 2015-07-14 Abbott Lab Vetores de expressão de mamífero melhorados e uso dos mesmos
KR101709141B1 (ko) 2008-01-25 2017-02-22 브이티브이 테라퓨틱스 엘엘씨 ＴＮＦ-α 합성의 조절자 및 ＰＤＥ4 억제제로서 3고리 화합물
GB0807413D0 (en) 2008-04-23 2008-05-28 Ucb Pharma Sa Biological products
EP2712921B1 (fr) 2008-05-06 2018-07-11 Astellas Institute for Regenerative Medicine Cellules formant des colonies hémangioblastiques et cellules hémangioblastiques non transplantables
KR20210003301A (ko) 2008-05-06 2021-01-11 아스텔라스 인스티튜트 포 리제너러티브 메디슨 다능성 줄기세포로부터 유도된 탈핵 적혈구계 세포를 생산하는 방법
US8598355B2 (en) 2008-05-14 2013-12-03 Astellas Pharma Inc. Amide compound
BRPI0909866B1 (pt) 2008-06-11 2021-08-24 Fresenius Medical Care Deutschland Gmbh Método de produção de um meio condicionado de células progenitoras de fígado, meio condicionado e composição farmacêutica
CN102066326A (zh) 2008-06-17 2011-05-18 安斯泰来制药株式会社 吡啶酮化合物
WO2009156960A2 (fr) 2008-06-27 2009-12-30 Pfizer Inc. Nouvelles compositions d'adjuvants
PL3581223T3 (pl) 2008-07-18 2024-11-25 UCB Biopharma SRL Systemy automatycznego podawania leków
EP2166021A1 (fr) 2008-09-16 2010-03-24 Ganymed Pharmaceuticals AG Anticorps monoclonaux pour le traitement du cancer
WO2010035012A1 (fr) 2008-09-26 2010-04-01 Ucb Pharma S.A. Produits biologiques
TW201024318A (en) 2008-10-20 2010-07-01 Abbott Lab Isolation and purification of antibodies using protein A affinity chromatography
SG195577A1 (en) 2008-10-20 2013-12-30 Abbott Lab Viral inactivation during purification of antibodies
US20100119492A1 (en) 2008-10-31 2010-05-13 Synthes Usa, Llc Method and device for activating stem cells
WO2010057870A1 (fr) 2008-11-18 2010-05-27 Ucb Pharma, S.A. Formules à libération prolongée comprenant un dérivé de 2-oxo-1-pyrrolidine
ES2385138T3 (es) 2008-12-16 2012-07-18 Astellas Pharma Inc. Modelo de roedor de enfermedad para dolor muscular crónico
BRPI1008692B8 (pt) 2009-02-17 2021-05-25 Ucb Biopharma Sprl anticorpo antagonista tendo especificidade para ox40 humano, sequência de dna isolado, vetor de clonagem ou de expressão, célula hospedeira, processo para a produção do referido anticorpo, composição farmacêutica, uso do 5 referido anticorpo e proteína de fusão
GB0904214D0 (en) 2009-03-11 2009-04-22 Ucb Pharma Sa Biological products
CN103585643A (zh) 2009-04-03 2014-02-19 梅里亚有限公司 运载新城疫病毒的禽疫苗
AU2010236256C1 (en) 2009-04-16 2015-10-22 Abbvie Biotherapeutics Inc. Anti-TNF-alpha antibodies and their uses
MX2011011541A (es) 2009-04-29 2012-02-28 Abbott Biotech Ltd Dispositivo de inyeccion automatico.
JP2012197228A (ja) 2009-07-27 2012-10-18 Kyoto Univ 肝炎の治療剤もしくは予防剤
ES2667258T3 (es) 2009-09-10 2018-05-10 Ucb Biopharma Sprl Anticuerpos multivalentes
US20110070227A1 (en) 2009-09-18 2011-03-24 Anna-Marie Novotney-Barry Treatment of Autoimmune and Inflammatory Diseases
WO2011036455A1 (fr) 2009-09-24 2011-03-31 Ucb Pharma S.A. Souche bactérienne pour l'expression de protéines recombinantes, ayant une degp à activité protéase déficiente et conservant une activité chaperonne et des gènes tsp et ptr inactivés
IN2012DN02401A (fr) 2009-09-24 2015-08-21 Ucb Pharma Sa
GB201005063D0 (en) 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
JP2012254939A (ja) 2009-10-07 2012-12-27 Astellas Pharma Inc オキサゾール化合物
GB0920127D0 (en) 2009-11-17 2009-12-30 Ucb Pharma Sa Antibodies
EP2501802A4 (fr) 2009-11-17 2013-08-21 Advanced Cell Tech Inc Procédés de génération de cellules humaines de l'épithélium pigmentaire rétinien (rpe) et préparations pharmaceutiques de celles-ci
GB0920324D0 (en) 2009-11-19 2010-01-06 Ucb Pharma Sa Antibodies
US9096879B2 (en) 2009-11-24 2015-08-04 Biogen Ma Inc. Method of supplementing culture media to prevent undesirable amino acid substitutions
JPWO2011071136A1 (ja) 2009-12-11 2013-04-22 アステラス製薬株式会社 線維筋痛症治療剤
US8758301B2 (en) 2009-12-15 2014-06-24 Abbvie Biotechnology Ltd Firing button for automatic injection device
WO2011073154A1 (fr) 2009-12-17 2011-06-23 Boehringer Ingelheim International Gmbh Nouveaux antagonistes du récepteur ccr2 et leurs utilisations
HRP20181173T1 (hr) 2009-12-22 2018-09-21 Ucb Biopharma Sprl Polivinilpirolidon za stabilizaciju čvrste disperzije nekristalnog oblika rotigotina
SG181628A1 (en) 2009-12-22 2012-07-30 Celldex Therapeutics Inc Vaccine compositions
GB201000467D0 (en) 2010-01-12 2010-02-24 Ucb Pharma Sa Antibodies
GB201000590D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial host strain
GB201000588D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial host strain
GB201000591D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial hoist strain
GB201000587D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial hoist strain
GB201001791D0 (en) 2010-02-03 2010-03-24 Ucb Pharma Sa Process for obtaining antibodies
EP2545078A1 (fr) 2010-03-11 2013-01-16 UCB Pharma, S.A. Anticorps pd-1
TW201134488A (en) 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
EP2371864A1 (fr) 2010-03-23 2011-10-05 Ganymed Pharmaceuticals AG Anticorps monoclonaux pour le traitement du cancer
GB201005064D0 (en) 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
EP2550297B1 (fr) 2010-03-25 2019-01-23 UCB Biopharma SPRL Molécules de dvd-lg stabilisées par un disulfure
NZ602020A (en) 2010-03-31 2014-05-30 Boehringer Ingelheim Int Anti-cd40 antibodies
PH12012501991A1 (en) 2010-04-07 2017-07-26 Abbvie Inc Tnf-alpha binding proteins
JP5786020B2 (ja) 2010-04-16 2015-09-30 アボットジャパン株式会社 関節リウマチを診断する方法および試薬
KR101850687B1 (ko) 2010-04-21 2018-04-20 애브비 바이오테크놀로지 리미티드 치료제의 제어된 전달을 위한 착용형 자동 주사 디바이스
SMT201900074T1 (it) 2010-05-04 2019-02-28 Five Prime Therapeutics Inc Anticorpi che legano csf1r
EP2571903B1 (fr) 2010-05-17 2019-09-04 EMD Millipore Corporation Polymères répondant à des stimuli pour la purification de biomolécules
EP2575878B1 (fr) 2010-05-28 2018-06-13 Zoetis Belgium S.A. Vaccins comprenants cholestérole et cpg comme seules molécules adjuvantes-porteuses
CA2801917C (fr) 2010-06-03 2017-04-25 Abbvie Biotechnology Ltd Utilisations et compositions pour le traitement de l'hidrosadenite (hs)
US8933228B2 (en) 2010-06-17 2015-01-13 Respivert, Ltd. Respiratory formulations and compounds for use therein
ES2703774T3 (es) 2010-06-18 2019-03-12 Xbiotech Inc Tratamiento para la artritis
AU2011280878B2 (en) 2010-07-23 2016-06-16 Astellas Institute For Regenerative Medicine Methods for detection of rare subpopulations of cells and highly purified compositions of cells
GB201012599D0 (en) 2010-07-27 2010-09-08 Ucb Pharma Sa Process for purifying proteins
GB201012603D0 (en) 2010-07-27 2010-09-08 Ucb Pharma Sa Protein purification
GB201012784D0 (en) 2010-07-29 2010-09-15 Ucb Pharma Sa Method
GB201014033D0 (en) 2010-08-20 2010-10-06 Ucb Pharma Sa Biological products
WO2012032489A1 (fr) 2010-09-10 2012-03-15 Wyeth Llc Variants non-lipidiques des antigènes orf 2086 de neisseria meningitidis
JP2013249256A (ja) 2010-09-15 2013-12-12 Astellas Pharma Inc 脂肪性肝疾患治療薬
UA112062C2 (uk) 2010-10-04 2016-07-25 Бьорінгер Інгельхайм Інтернаціональ Гмбх Cd33-зв'язувальний агент
CA2814652C (fr) 2010-10-13 2021-05-18 Janssen Biotech, Inc. Anticorps contre l'oncostatine m humaine et procedes d'utilisation
SG190006A1 (en) 2010-11-04 2013-06-28 Boehringer Ingelheim Int Anti-il-23 antibodies
CN103458926B (zh) 2010-11-11 2016-10-26 艾伯维生物技术有限公司 改进的高浓度抗TNF α 抗体液体制剂
JP6027539B2 (ja) 2010-12-02 2016-11-16 ウーツェーベー ファルマ ゲーエムベーハーＵｃｂ Ｐｈａｒｍａ Ｇｍｂｈ ラコサミドの１日１回投与用製剤
AR084210A1 (es) 2010-12-08 2013-05-02 Abbott Lab PROTEINAS DE UNION AL TNF-a
US10208349B2 (en) 2011-01-07 2019-02-19 Ucb Biopharma Sprl Lipocalin 2 as a biomarker for IL-17 inhibitor therapy efficacy
ME02734B (fr) 2011-01-14 2017-10-20 Ucb Biopharma Sprl Molécules d'anticorps se liant à il-17a et il-17f
RU2602039C2 (ru) 2011-01-24 2016-11-10 Эббви Байотекнолоджи Лтд. Автоматические инъекционные устройства, имеющие наформованные поверхности захвата
US9170249B2 (en) 2011-03-12 2015-10-27 Momenta Pharmaceuticals, Inc. N-acetylhexosamine-containing N-glycans in glycoprotein products
TW201249867A (en) 2011-04-01 2012-12-16 Astellas Pharma Inc Novel anti-human il-23 receptor antibody
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
ES2764079T3 (es) 2011-05-27 2020-06-02 Boehringer Ingelheim Animal Health Usa Inc Vacunas genéticas contra el virus Hendra y el virus Nipah
PL2714162T3 (pl) 2011-05-27 2020-08-24 Boehringer Ingelheim International Gmbh Inhalator i kapsułka do inhalatora
ES2542250T3 (es) 2011-06-02 2015-08-03 Ucb Biopharma Sprl Autoinyector
UY34105A (es) 2011-06-03 2012-07-31 Lg Life Sciences Ltd Formulación líquida estable de etanercept
WO2013009648A2 (fr) 2011-07-08 2013-01-17 Momenta Pharmaceuticals, Inc. Procédé de culture cellulaire
EP2734537B1 (fr) 2011-07-20 2022-12-21 Zepteon, Incorporated Procédés de séparation de polypeptide
LT2741740T (lt) 2011-08-12 2017-08-10 Merial, Inc. Biologinių produktų, ypatingai vakcinų, vakuuminis konservavimas
US9802954B2 (en) 2011-08-24 2017-10-31 Boehringer Ingelheim International Gmbh Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma
HRP20182194T1 (hr) 2011-09-08 2019-02-22 New York University Onkolitički herpes simpleks virus i njegova terapeutska uporaba
ES2691492T3 (es) 2011-09-22 2018-11-27 Abbvie Inc. Porta-jeringa para un dispositivo automático de inyección
MX356808B (es) 2011-09-23 2018-06-14 Xbiotech Inc Uso de una composición farmacéutica que comprende un anticuerpo anti-il-1a para el tratamiento de la caquexia.
EP2578582A1 (fr) 2011-10-03 2013-04-10 Respivert Limited 1-Pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napthtalèn-1-yl) urées comme inhibiteurs de la p38 MAP kinase
PE20142355A1 (es) 2011-10-03 2015-01-10 Respivert Ltd 1-pirazolil-3-(4-((2-anilinopirimidin-4-il)oxi)naftalen-1-il)ureas como inhibidores de proteinas cinasas activadas por mitogeno p38
US10493151B2 (en) 2011-10-18 2019-12-03 Coherus Biosciences, Inc. Etanercept formulations stabilized with sodium chloride
SG11201401562RA (en) 2011-10-18 2014-09-26 Coherus Biosciences Inc Etanercept formulations stabilized with sodium chloride
AR088512A1 (es) 2011-10-24 2014-06-18 Abbvie Inc Anticuerpos dirigidos contra el tnf
WO2013066707A1 (fr) 2011-10-31 2013-05-10 Merck Sharp & Dohme Corp. Procédé de chromatographie permettant de décomposer des agrégats d'anticorps hétérogènes
UA112203C2 (uk) 2011-11-11 2016-08-10 Юсб Фарма С.А. Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини
US9803004B2 (en) 2011-11-11 2017-10-31 Ucb Biopharma Sprl Albumin binding antibodies and binding fragments thereof
IL287381B2 (en) 2011-11-14 2024-04-01 Astellas Inst For Regenerative Medicine Pharmaceutical preparations of human rpe cells and uses thereof
RS57886B1 (sr) 2011-11-30 2019-01-31 Astellas Inst For Regenerative Medicine Mezenhimalne stromalne ćelije i primene vezane za njih
US8961956B2 (en) 2011-11-30 2015-02-24 Ocata Therapeutics, Inc. Mesenchymal stromal cells and uses related thereto
DE102011087676A1 (de) 2011-12-02 2013-06-06 Continental Automotive Gmbh Verfahren und Vorrichtung zur Überprüfung einer Lautsprecheranordnung
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
GB201203051D0 (en) 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
GB201203071D0 (en) 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
PL2821416T3 (pl) 2012-02-28 2019-01-31 Astellas Pharma Inc. Nowe przeciwciało przeciwko ludzkiemu receptorowi IL-23
US9443445B2 (en) 2012-03-02 2016-09-13 Abbvie Inc. Automatic injection training device
US10093728B2 (en) 2012-03-07 2018-10-09 Cadila Healthcare Limited Pharmaceutical formulations of TNF-alpha antibodies
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
BR122020002414B1 (pt) 2012-03-15 2022-03-03 Janssen Biotech, Inc Uso de anticorpos anti-cd27 humanos
KR102951567B1 (ko) 2012-03-22 2026-04-10 뵈링거 잉겔하임 애니멀 헬스 유에스에이 인코포레이티드 개질된 마렉병 바이러스, 및 이로부터 제조된 백신
WO2013158273A1 (fr) 2012-04-20 2013-10-24 Abbvie Inc. Procédés de modulation de la distribution de variant de lysine c-terminal
WO2013158279A1 (fr) 2012-04-20 2013-10-24 Abbvie Inc. Procédés de purification de protéines pour réduire des espèces acides
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
SI2844637T1 (en) 2012-05-02 2018-07-31 Boehringer Ingelheim International Gmbh Substituted 3-haloallylamine inhibitors of ssao and uses thereof
RU2737765C2 (ru) 2012-05-04 2020-12-02 Пфайзер Инк. Простатоассоциированные антигены и иммунотерапевтические схемы на основе вакцин
GB201208367D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Biological product
GB201208370D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Antibodies
WO2013174403A1 (fr) 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Polythérapie impliquant des anticorps dirigés contre la claudine 18,2 pour le traitement du cancer
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
CA2874303C (fr) 2012-06-11 2020-10-13 Ucb Biopharma Sprl Benzimidazoles modulant l'activite tnf -alpha
US20150150982A1 (en) 2012-06-12 2015-06-04 Boehringer Ingelheim International Gmbh Pharmaceutical formulation for a therapeutic antibody
MX2014014717A (es) 2012-06-21 2015-03-06 Ucb Pharma Sa Formulacion farmaceutica.
US9309243B2 (en) 2012-07-13 2016-04-12 Ucb Biopharma Sprl Imidazopyridine derivatives as modulators of TNF activity
GB201212513D0 (en) 2012-07-13 2012-08-29 Ucb Pharma Sa Therapeutic agents
JP2015180606A (ja) 2012-08-01 2015-10-15 アステラス製薬株式会社 抗癌剤の併用による癌治療方法
WO2014020171A1 (fr) 2012-08-03 2014-02-06 Boehringer Ingelheim International Gmbh Capacité tampon d'anticorps
MA37830B1 (fr) 2012-08-10 2018-09-28 Boehringer Ingelheim Int Composés hétéroromatiques en tant qu'inhibiteurs de la tyrosine kinase de bruton (btk)
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
KR20150043523A (ko) 2012-09-02 2015-04-22 애브비 인코포레이티드 단백질 불균일성의 제어 방법
MX2015003007A (es) 2012-09-07 2015-06-05 Coherus Biosciences Inc Formulaciones acuosas estables de adalimumab.
AU2013315750B9 (en) 2012-09-11 2018-11-15 Coherus Biosciences, Inc. Correctly folded etanercept in high purity and excellent yield
LT2897978T (lt) 2012-09-19 2017-06-12 Abbvie Biotherapeutics Inc. Antikūnų su sumažintu imunogeniškumu identifikavimo būdas
BR122016023101B1 (pt) 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
CN105008344B (zh) 2012-11-02 2017-07-25 辉瑞公司 布鲁顿氏酪氨酸激酶抑制剂
RU2664541C2 (ru) 2012-11-13 2018-08-20 Эррэй Биофарма Инк. Бициклические соединения мочевины, тиомочевины, гуанидина и цианогуанидина, пригодные для лечения боли
WO2014075697A1 (fr) 2012-11-13 2014-05-22 Biontech Ag Agents de traitement de maladies cancéreuses exprimant claudine
EP2934587A4 (fr) 2012-12-18 2016-08-03 Merck Sharp & Dohme Formulations liquides pour un anticorps anti-tnfalpha
SG11201504649RA (en) 2012-12-20 2015-07-30 Merck Patent Gmbh Copolymers for protein precipitation
ES2933127T3 (es) 2012-12-20 2023-02-01 Pfizer Procedimiento de glucoconjugación
UA111305C2 (uk) 2012-12-21 2016-04-11 Пфайзер Інк. Конденсовані лактами арилу та гетероарилу
GB201223276D0 (en) 2012-12-21 2013-02-06 Ucb Pharma Sa Antibodies and methods of producing same
CN114558032B (zh) 2012-12-21 2025-07-29 安斯泰来再生医药协会 由多能干细胞制备血小板的方法及其组合物
JP6533932B2 (ja) 2012-12-28 2019-06-26 アボット カーディオバスキュラー システムズ インコーポレイテッド 抗体を含む治療用組成物
EP2752426A1 (fr) 2013-01-03 2014-07-09 Covagen AG Composés de liaison d'albumine de sérum humain et leurs protéines de fusion
GB201300683D0 (en) 2013-01-15 2013-02-27 Apitope Int Nv Peptide
JP2016093104A (ja) 2013-02-19 2016-05-26 国立大学法人京都大学 抗ヒトＣＤ３ε抗体又はそのフラグメント、及びそれを有効成分とする免疫抑制剤
EP2959909B1 (fr) 2013-02-20 2019-12-18 Samsung Life Public Welfare Foundation Composition pour le traitement de maladies inflammatoires du cerveau comprenant une cellule souche comme principe actif
WO2014127785A1 (fr) 2013-02-20 2014-08-28 Ganymed Pharmaceuticals Ag Polythérapie impliquant des anticorps dirigés contre la claudine 18,2 pour le traitement du cancer
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
AU2014230814B2 (en) 2013-03-14 2017-12-21 Boehringer Ingelheim International Gmbh Substituted 2-Aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of Cathepsin C
US9217168B2 (en) 2013-03-14 2015-12-22 Momenta Pharmaceuticals, Inc. Methods of cell culture
WO2014151878A2 (fr) 2013-03-14 2014-09-25 Abbvie Inc. Procédés pour la modulation des profils de glycosylation de protéines de traitements à base de protéines recombinantes au moyen de monosaccharides et d'oligosaccharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
AU2014237635B2 (en) 2013-03-15 2020-03-12 Janssen Biologics B.V. Manufacturing methods to control C-terminal lysine, galactose and sialic acid content in recombinant proteins
DK2970378T3 (da) 2013-03-15 2021-08-23 Biogen Ma Inc Hydrofob interaktionsproteinkromatografi under saltfrie betingelser
KR102527507B1 (ko) 2013-03-15 2023-04-28 아스텔라스 인스티튜트 포 리제너러티브 메디슨 만능 줄기 세포로부터 제조된 광수용기 및 광수용기 전구체
MD20180107A2 (ro) 2013-03-18 2019-06-30 Biocerox Products B.V. Anticorpi anti-CD134 (OX40) umanizaţi şi utilizarea acestora
WO2014146672A1 (fr) 2013-03-18 2014-09-25 Ganymed Pharmaceuticals Ag Thérapie comprenant des anticorps dirigés contre cldn 18.2 pour le traitement du cancer
JP2016000003A (ja) 2013-04-19 2016-01-07 アステラス製薬株式会社 新規抗ヒトｔｗｅａｋ抗体
EP3683312B1 (fr) 2013-04-23 2022-09-07 Elasmogen Limited Bibliothèque synthétique de molécules de liaison spécifiques
JP6294872B2 (ja) 2013-04-26 2018-03-14 国立大学法人京都大学 脳動脈瘤の形成および／または増大の抑制若しくは縮小用医薬組成物
TW201446961A (zh) 2013-05-06 2014-12-16 Abbvie Inc 用於細胞培養之組合物及其使用方法
EP2803668A1 (fr) 2013-05-17 2014-11-19 Boehringer Ingelheim International Gmbh Nouveau (cyano-dimethyl-methyl)-isoxazoles et - [1,3,4] thiadiazoles
EP2999459A1 (fr) 2013-05-22 2016-03-30 UCB Biopharma SPRL Procédés pour produire des particules contenant des protéines thérapeutiques
EP3003369A4 (fr) 2013-05-28 2017-04-26 Momenta Pharmaceuticals, Inc. Compositions pharmaceutiques comprenant un pyrophosphate
TWI596107B (zh) 2013-06-25 2017-08-21 卡地拉保健有限公司 單株抗體之新穎純化方法
HK1218297A1 (zh) 2013-07-06 2017-02-10 Cadila Healthcare Limited 用於生产单克隆抗体的改进方法
US9856502B2 (en) 2013-07-23 2018-01-02 Biocon Limited Methods for controlling fucosylation levels in proteins
CN105745081B (zh) 2013-07-28 2019-10-25 惠普工业印刷有限公司 介质支承装置
GEP20186876B (en) 2013-08-02 2018-07-10 Pfizer Heterobicycloaryl rorc2 inhibitors and methods of use thereof
KR101809072B1 (ko) 2013-08-02 2017-12-14 화이자 인코포레이티드 항-cxcr4 항체 및 항체-약물 접합체
GB201313888D0 (en) 2013-08-02 2013-09-18 Consort Medical Plc Assembly for an autoinjector device
LT3031913T (lt) 2013-08-09 2019-05-27 Astellas Pharma Inc. Naujas antikūnas, atpažįstantis žmogaus tslp receptorių
PL3036320T5 (pl) 2013-08-19 2024-06-10 Biogen Ma Inc. Kontrola glikozylacji białka poprzez parametry procesu suplementacji pożywki hodowlanej i hodowli komórkowej
US20160237399A1 (en) 2015-02-18 2016-08-18 Biogen Ma Inc. Control of Protein Glycosylation by Culture Medium Supplementation and Cell Culture Process Parameters
AU2014310480B2 (en) 2013-08-23 2020-03-05 Boehringer Ingelheim Rcv Gmbh & Co Kg Microparticles for cell disruption and/or biomolecule recovery
GB201315487D0 (en) 2013-08-30 2013-10-16 Ucb Pharma Sa Antibodies
US20160192626A1 (en) 2013-09-18 2016-07-07 Kyoto University Method For Creating Endometriotic Cells And Endometriosis Model Animal
EP3048899B1 (fr) 2013-09-25 2021-09-08 Bioverativ Therapeutics Inc. Procédés d'inactivation de virus sur colonne
JP6526025B2 (ja) 2013-10-16 2019-06-05 オンコバイオロジクス，インコーポレイティド 抗体安定性を増強する緩衝液製剤
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
GB201320066D0 (en) 2013-11-13 2013-12-25 Ucb Pharma Sa Biological products
EP3068801A1 (fr) 2013-11-13 2016-09-21 Pfizer Inc. Anticorps spécifiques du ligand 1a de type facteur de nécrose tumorale et compositions ainsi qu'utilisations associées
WO2015073884A2 (fr) 2013-11-15 2015-05-21 Abbvie, Inc. Compositions de protéines de liaison génétiquement glycomodifiées
WO2015086519A1 (fr) 2013-12-09 2015-06-18 Ucb Biopharma Sprl Dérivés d'imidazopyridine comme modulateurs de l'activité du tnf
GB201321739D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321738D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
GB201321745D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321734D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
GB201321737D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
GB201321740D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321744D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
EP3080085B1 (fr) 2013-12-09 2019-08-14 UCB Biopharma SPRL Dérivés hetero-aromatiques bicycliques condenses utilisables en tant que modulateurs de l'activité tnf
GB201321731D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321741D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321743D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321732D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321746D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321733D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321736D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321735D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
GB201321728D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321742D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321729D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321748D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321730D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321749D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
CN104707146B (zh) * 2013-12-16 2019-04-16 浙江海正药业股份有限公司 一种含有阿达木单抗的药物组合物
EP4043493A1 (fr) 2013-12-24 2022-08-17 Janssen Pharmaceutica NV Anticorps anti-vista et fragments
CN114292331A (zh) 2013-12-24 2022-04-08 安斯泰来制药株式会社 抗人bdca-2抗体、其生产方法、多核苷酸、表达载体、宿主细胞及医药组合物
EP3088517B1 (fr) 2013-12-26 2023-11-01 Mitsubishi Tanabe Pharma Corporation Anticorps monoclonal neutralisant humain anti-il-33
KR20210032013A (ko) 2014-01-21 2021-03-23 화이자 인코포레이티드 스트렙토코쿠스 뉴모니아에 피막 폴리사카라이드 및 그의 접합체
US10342925B2 (en) 2014-01-27 2019-07-09 Ucb Biopharma Sprl Auto-injector
PL3348556T3 (pl) 2014-01-29 2020-11-02 UCB Biopharma SRL Heteroaryloamidy jako inhibitory agregacji białka
WO2016039801A1 (fr) 2014-01-31 2016-03-17 Boehringer Ingelheim International Gmbh Nouveaux anticorps anti-baff
EP3102589A1 (fr) 2014-02-04 2016-12-14 Biogen MA Inc. Chromatographie par échange cationique utilisée dans le mode de fixation par écoulement pour enrichir les modifications post-traductionnelles
PT3357919T (pt) 2014-02-14 2020-02-20 Respivert Ltd Compostos heterocíclicos aromáticos como compostos antiinflamatórios
USRE47493E1 (en) 2014-02-20 2019-07-09 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
CA2941014A1 (fr) 2014-02-28 2015-09-03 Astellas Pharma Inc. Nouvel anticorps bispecifique se liant au tlr2 humain et au tlr4 humain
US10323095B2 (en) 2014-03-17 2019-06-18 Mitsubishi Tanabe Pharma Corporation Antibody-fynomer conjugates
US9135573B1 (en) 2014-03-17 2015-09-15 Linkedin Corporation Estimating reputation scores in reputation systems
CA2942997C (fr) 2014-03-19 2022-09-13 Boehringer Ingelheim International Gmbh Inhibiteurs de sik de type heteroaryle
TW201623277A (zh) 2014-03-26 2016-07-01 安斯泰來製藥股份有限公司 醯胺化合物
EP3125928A4 (fr) 2014-04-02 2017-11-29 Intas Pharmaceuticals Ltd. Composition pharmaceutique liquide d'adalimumab
WO2015150995A1 (fr) 2014-04-04 2015-10-08 Pfizer Inc. Composés à base d'hétéroaryle ou d'aryle fusionné-bicyclique et leur utilisation comme composés inhibiteurs de l'irak 4
EP4234569A3 (fr) 2014-04-15 2023-10-18 Boehringer Ingelheim International GmbH Procédé et utilisation d'inactivation continue de virus pendant la fabrication de produit biologique
SG10201809152QA (en) 2014-04-17 2018-11-29 Boehringer Ingelheim Rcv Gmbh Recombinant host cell for expressing proteins of interest
KR102092225B1 (ko) 2014-04-30 2020-03-23 주식회사 엘지화학 고효율 분비능을 가지는 단백질 분비 인자 및 이를 포함하는 발현 벡터
US10392438B2 (en) 2014-05-16 2019-08-27 Pfizer Inc. Bispecific antibodies
EP2946767B1 (fr) 2014-05-23 2016-10-05 Ares Trading S.A. Composition pharmaceutique liquide
ES2572919T3 (es) 2014-05-23 2016-06-03 Ares Trading S.A. Composición farmacéutica líquida
PL2946765T3 (pl) 2014-05-23 2017-08-31 Ares Trading S.A. Ciekła kompozycja farmaceutyczna
GB201409558D0 (en) 2014-05-29 2014-07-16 Ucb Biopharma Sprl Method
ES2864079T3 (es) 2014-05-30 2021-10-13 Pfizer Derivados de carbonitrilo como moduladores selectivos del receptor de andrógenos
KR20170018810A (ko) 2014-06-10 2017-02-20 메이지 세이카 파루마 가부시키가이샤 안정한 아달리무맙 수성 제제
AP2016009605A0 (en) 2014-06-17 2016-12-31 Pfizer Substituted dihydroisoquinolinone compounds
TWI713453B (zh) 2014-06-23 2020-12-21 美商健生生物科技公司 干擾素α及ω抗體拮抗劑
GB201412659D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
GB201412658D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
WO2016014775A1 (fr) 2014-07-24 2016-01-28 Boehringer Ingelheim International Gmbh Biomarqueurs utiles dans le traitement de maladies associées à l'il-23a
JP6627761B2 (ja) 2014-08-06 2020-01-08 アステラス製薬株式会社 新規抗ヒトＩｇβ抗体
SG11201700243YA (en) 2014-08-06 2017-02-27 Pfizer Imidazopyridazine compounds
AR101479A1 (es) 2014-08-11 2016-12-21 Boehringer Ingelheim Int Derivados de 6-alquinil-piridina
NO2721710T3 (fr) 2014-08-21 2018-03-31
JP2017527564A (ja) 2014-09-03 2017-09-21 バヴァリアン ノルディック エー／エス 免疫応答の増進を目的とする方法及び組成物
US10435464B1 (en) 2014-09-05 2019-10-08 Coherus Biosciences, Inc. Methods for making recombinant proteins
JP6778181B2 (ja) 2014-09-05 2020-10-28 アステラス インスティテュート フォー リジェネレイティブ メディシン 網膜神経節細胞およびその前駆体
UA118610C2 (uk) 2014-09-12 2019-02-11 Бьорінгер Інгельхайм Інтернаціональ Гмбх Спіроциклічні інгібітори катепсину c
ES2897782T3 (es) 2014-09-17 2022-03-02 Merck Patent Gmbh Método de tratamiento de las enfermedades de la metástasis ósea, medicamentos para el tratamiento y método para predecir el resultado clínico del tratamiento de las enfermedades causadas por metástasis ósea
HUE068152T2 (hu) 2014-09-25 2024-12-28 Boehringer Ingelheim Vetmedica Gmbh SGLT2-gátlók és dopamin agonisták kombinációs kezelése anyagcserezavarok megelõzésére lófélékben
MA40759A (fr) 2014-09-26 2017-08-01 Pfizer Modulateurs de rorc2 de type pyrrolopyridine substitué par un méthyle et trifluorométhyle et leurs procédés d'utilisation
PE20170693A1 (es) 2014-10-03 2017-06-13 Ucb Biopharma Sprl Derivados de imidazol pentaciclicos fusionados
HUP1400510A1 (hu) * 2014-10-28 2016-05-30 Richter Gedeon Nyrt Gyógyászati TNFalfa ellenes antitest készítmény
US10213452B2 (en) 2014-10-31 2019-02-26 Fresenius Medical Care Deutschland Gmbh Pharmaceutical compositions containing steviosides
KR102265924B1 (ko) 2014-10-31 2021-06-15 삼성바이오에피스 주식회사 Pdk 불활성화에 의한 폴리펩타이드의 생산
CA2965566A1 (fr) 2014-11-14 2016-05-19 Boehringer Ingelheim International Gmbh Amides de morpholine et de 1,4-oxazepane utilises en tant qu'agonistes du sous-type 4 du recepteur de la somatostatine (sstr4)
CN107108743B (zh) 2014-12-03 2021-05-04 (株)爱恩德生物 结合神经毡蛋白1的抗体及其用途
KR20160068558A (ko) 2014-12-05 2016-06-15 삼성바이오에피스 주식회사 마우스 cmv 프로모터를 포함하는 융합 폴리뉴클레오타이드 및 이를 이용한 목적 폴리펩타이드의 생산 방법
AU2015371381A1 (en) 2014-12-22 2017-07-20 Ares Trading S.A. Liquid pharmaceutical composition
PL3237432T3 (pl) 2014-12-22 2024-03-04 UCB Biopharma SRL Wytwarzanie białka
FI3237433T3 (fi) 2014-12-22 2025-10-14 UCB Biopharma SRL Menetelmä proteiinin valmistamiseksi
EP3237000A1 (fr) * 2014-12-23 2017-11-01 Pfizer Inc Formulation d'anticorps aqueuse stable pour des anticorps anti tnf alpha
US10696735B2 (en) 2015-01-21 2020-06-30 Outlook Therapeutics, Inc. Modulation of charge variants in a monoclonal antibody composition
AR103544A1 (es) * 2015-01-28 2017-05-17 Mabxience S A FORMULACIONES FARMACÉUTICAS PARA ANTICUERPOS ANTI-TNF-a
GB201501613D0 (en) 2015-01-30 2015-03-18 Ucb Biopharma Sprl Treatment of autoimmune disorders with CD154 antibodies
JP2018510131A (ja) 2015-01-30 2018-04-12 ファイザー・インク Ｒｏｒｃ２のスルホンアミド置換インドールモジュレーターおよびその使用方法
US10336748B2 (en) 2015-01-30 2019-07-02 Pfizer Inc. Methyoxy-substituted pyrrolopyridine modulators of RORC2 and methods of use thereof
EP3053572A1 (fr) 2015-02-06 2016-08-10 Ares Trading S.A. Composition pharmaceutique liquide
US20180008707A1 (en) * 2015-02-13 2018-01-11 Sanofi Stable liquid formulation for monoclonal antibodies
WO2016149139A1 (fr) 2015-03-13 2016-09-22 Samsung Bioepis Co., Ltd. Composition contenant un polypeptide anti-tnf-alpha et utilisation
KR20240093910A (ko) 2015-04-01 2024-06-24 베링거 인겔하임 인터내셔날 게엠베하 세포 배양 배지
WO2016162819A1 (fr) * 2015-04-07 2016-10-13 Lupin Limited Composition pharmaceutique aqueuse stable d'anticorps anti-tnf alpha
EP3078675A1 (fr) 2015-04-10 2016-10-12 Ares Trading S.A. Régime de dosage à induction pour le traitement des maladies liées au tnf alpha
TWI700298B (zh) 2015-04-13 2020-08-01 美商輝瑞股份有限公司 靶向ｂ細胞成熟抗原之嵌合型抗原受體類
MX2017013156A (es) 2015-04-14 2018-02-21 Boehringer Ingelheim Int Metodos para tratar enfermedades.
EP3081227A1 (fr) 2015-04-15 2016-10-19 Institut National De La Recherche Agronomique Lactococcus lactis produisant du tslp ou il-25 et leurs utilisations comme probiotiques et thérapeutiques
WO2016165765A1 (fr) 2015-04-15 2016-10-20 Ganymed Pharmaceuticals Ag Procédés et compositions permettant de prédire l'efficacité thérapeutique des traitements contre le cancer et de pronostiquer un cancer
GB201506786D0 (en) 2015-04-21 2015-06-03 Ucb Biopharma Sprl Therapeutic use
PE20180251A1 (es) 2015-04-28 2018-02-02 Mitsubishi Tanabe Pharma Corp PROTEINA DE UNIION A RGMa Y SU USO
HK1245646A1 (zh) 2015-04-28 2018-08-31 安斯泰来制药有限公司 口服给药用医药组合物
EP3288584A2 (fr) 2015-04-30 2018-03-07 President and Fellows of Harvard College Anticorps anti-ap2 et agents de liaison à l'antigène utilisables en vue du traitement d'affections métaboliques
TWI807252B (zh) 2015-05-04 2023-07-01 美商輝瑞股份有限公司 Ｂ型鏈球菌多醣-蛋白質軛合物、製造軛合物之方法、含軛合物之免疫原性組成物、及其用途
JP6851322B2 (ja) 2015-05-27 2021-03-31 ユーシービー バイオファルマ エスアールエル 神経疾患を治療する方法
EP3303561A2 (fr) 2015-05-29 2018-04-11 Biogen MA Inc. Méthodes et systèmes de culture cellulaire
US10308615B2 (en) 2015-05-29 2019-06-04 Pfizer Inc. Heterocyclic compounds as inhibitors of Vanin-1 enzyme
GB201509888D0 (en) 2015-06-08 2015-07-22 Ucb Biopharma Sprl Therapeutic agents
GB201509893D0 (en) 2015-06-08 2015-07-22 Ucb Biopharma Sprl Therapeutic agents
GB201509885D0 (en) 2015-06-08 2015-07-22 Ucb Biopharma Sprl Therapeutic agents
ES2832893T3 (es) 2015-06-17 2021-06-11 Pfizer Compuestos tricíclicos y su uso como inhibidores de la fosfodiesterasa
GB201510758D0 (en) 2015-06-18 2015-08-05 Ucb Biopharma Sprl Novel TNFa structure for use in therapy
AR105025A1 (es) 2015-06-19 2017-08-30 Astellas Pharma Inc Compuesto de imidazodiazepina
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
JP2018519344A (ja) 2015-07-03 2018-07-19 アステラス ファーマ ユーロープ リミテッド チアクマイシン化合物の新規の投薬レジメン
MX2017015908A (es) 2015-07-06 2018-03-15 Ucb Biopharma Sprl Anticuerpos de union a tau.
EA037092B1 (ru) 2015-07-06 2021-02-04 Юсб Биофарма Срл Тау-связывающие антитела
KR102225282B1 (ko) 2015-07-21 2021-03-10 화이자 인코포레이티드 접합된 캡슐형 사카라이드 항원을 포함하는 면역원성 조성물, 그를 포함하는 키트 및 그의 용도
UA125433C2 (uk) 2015-07-23 2022-03-09 Бьорінґер Інґельхайм Інтернаціональ Ґмбх Націлена на іl-23а і фактор активації в-лімфоцитів (baff) сполука та її застосування
PT3333165T (pt) 2015-08-04 2019-10-29 Astellas Pharma Inc Derivado de piperazina
SG10201913250SA (en) 2015-08-18 2020-03-30 Astellas Inst For Regenerative Medicine Clinical formulations
RS61719B1 (sr) 2015-08-27 2021-05-31 Pfizer Biciklična fuzionisana hetaroaril ili aril jedinjenja kao modulatori irak4
US20170058038A1 (en) 2015-09-01 2017-03-02 Boehringer Ingelheim International Gmbh Use of anti-cd40 antibodies for treatment of lupus nephritis
ES2974666T3 (es) 2015-09-29 2024-07-01 Boehringer Ingelheim Animal Health Usa Inc Vacunas de partículas similares a virus (VLP) del parvovirus canino (CPV) y usos de las mismas
BR112018006360A2 (pt) 2015-09-30 2018-10-09 Janssen Biotech Inc anticorpos agonísticos que se ligam especificamente ao cd40 humano e métodos de uso
DK3359688T3 (da) 2015-10-05 2021-08-23 Biogen Ma Inc Molekylære signaturer til anvendelse til diagnose og analyse af respons på behandling af autoimmune sygdomme
KR101949451B1 (ko) 2015-10-13 2019-05-10 주식회사 이노파마스크린 염증성 장 질환 및 아토피 피부염 치료용 조성물
EP3365335B1 (fr) 2015-10-23 2024-02-14 Array Biopharma, Inc. Composés de 2-pyridazin-3(2h)-one à substitution 2-aryle et 2-hétéroaryle utilisés en tant qu'inhibiteurs de fgfr tyrosine kinases
MY207225A (en) 2015-10-27 2025-02-06 UCB Biopharma SRL Methods of treatment using anti-il-17a/f antibodies
US20170121420A1 (en) 2015-11-02 2017-05-04 Janssen Pharmaceutica Nv Anti-il1rap antibodies, bispecific antigen binding molecules that bind il1rap and cd3, and uses thereof
US10421717B2 (en) 2015-11-03 2019-09-24 Ucb Biopharma Sprl Process for preparing brivaracetam
BR112018010494A8 (pt) 2015-11-23 2019-02-26 Merial Inc proteínas de fusão fmdv e e2 e seus usos
TWI703160B (zh) 2015-11-30 2020-09-01 美商輝瑞股份有限公司 用於部位專一性接合之抗體和抗體片段
GB201521389D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Method
GB201521391D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521393D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521382D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521383D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl And Ucb Celltech Method
PE20181074A1 (es) 2015-12-16 2018-07-04 Boehringer Ingelheim Int Compuestos heteroaromaticos como inhibidores de btk
WO2017104778A1 (fr) 2015-12-18 2017-06-22 アステラス製薬株式会社 Composition pharmaceutique contenant un anticorps anti-récepteur de la tslp humaine
GB201522391D0 (en) 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibody molecules
US10570118B2 (en) 2016-01-13 2020-02-25 Boehringer Ingelheim International Gmbh Isoquinolones as BTK inhibitors
ES2811523T3 (es) 2016-01-19 2021-03-12 Pfizer Vacunas contra el cáncer
ES3041841T3 (en) 2016-01-19 2025-11-14 Janssen Pharmaceutica Nv Formulations/compositions comprising a btk inhibitor
CN108472259A (zh) 2016-01-19 2018-08-31 詹森药业有限公司 包含btk抑制剂的配制品/组合物
CN109219618B (zh) 2016-01-21 2022-08-09 辉瑞大药厂 针对表皮生长因子受体变体iii和cd3的单特异性和双特异性抗体及其用途
EP3405481B1 (fr) 2016-01-21 2023-01-18 Pfizer Inc. Récepteurs antigéniques chimériques ciblant le variant iii du récepteur du facteur de croissance épidermique
MA46681A (fr) 2016-01-28 2019-09-11 Janssen Biotech Inc Anticorps bispécifiques anti-tnf-alpha/il-17a antibodies et anticorps anti-tnf-alpha et leurs procédés d'utilisation
TWI760322B (zh) 2016-01-29 2022-04-11 美商百靈佳殷格翰動物保健美國有限公司 重組腺病毒載體裝載之fmdv疫苗及其用途
US10465003B2 (en) 2016-02-05 2019-11-05 Janssen Biotech, Inc. Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes
EP3413915A1 (fr) 2016-02-08 2018-12-19 Synaffix B.V. Conjugués d'anticorps à indice thérapeutique amélioré permettant de cibler des tumeurs positives pour le her2 et méthode pour améliorer l'indice thérapeutique de conjugués d'anticorps
DE102016001407A1 (de) 2016-02-09 2017-08-24 Fresenius Medical Care Deutschland Gmbh Blutbehandlung mit Inaktivierung von freien Nukleinsäuren
GB201602938D0 (en) 2016-02-19 2016-04-06 Ucb Biopharma Sprl Protein purification
GB201603104D0 (en) 2016-02-23 2016-04-06 Ucb Biopharma Sprl Therapeutic agents
PL3419979T3 (pl) 2016-02-23 2020-06-29 Pfizer Inc. Związki 6,7-dihydro-5h-pirazolo[5,1-b][1,3]oksazyno-2- karboksyamidowe
ES2794779T3 (es) 2016-02-24 2020-11-19 Pfizer Derivados de pirazolo[1,5-a]pirazin-4-ilo como inhibidores de JAK
US10611800B2 (en) 2016-03-11 2020-04-07 Pfizer Inc. Human cytomegalovirus gB polypeptide
SG11201807824UA (en) 2016-03-11 2018-10-30 Boehringer Ingelheim Int Methods for continuously inactivating a virus during manufacture of a protein
WO2017159653A1 (fr) 2016-03-15 2017-09-21 アステラス製薬株式会社 Comprimé
US10519479B1 (en) 2016-03-15 2019-12-31 Ares Trading S.A. Methods for modifying glycosylation using manganese
US10526631B1 (en) 2016-03-15 2020-01-07 Ares Trading S.A. Method of reducing serine for asparagine misincorporation
KR102023058B1 (ko) 2016-03-25 2019-09-19 사회복지법인 삼성생명공익재단 이중 이온 pH-민감성 공중합체를 이용한 허혈성 뇌질환 치료용 약물 전달체
MX2018011975A (es) 2016-03-29 2019-01-15 Astellas Pharma Inc Terapia de combinacion para tratamiento de leucemia mieloide aguda.
EA201892142A1 (ru) 2016-04-01 2019-04-30 Юсб Байофарма Спрл Конденсированные пентациклические производные имидазола в качестве модуляторов активности tnf
US10793578B2 (en) 2016-04-01 2020-10-06 UCB Biopharma SRL Fused pentacyclic imidazole derivatives as modulators of TNF activity
EP3436459B1 (fr) 2016-04-01 2021-08-25 UCB Biopharma SRL Dérivés d'imidazole pentacyclique fusionnés comme modulateurs de l'activité de la tnf
US10766906B2 (en) 2016-04-01 2020-09-08 UCB Biopharma SRL Fused hexacyclic imidazole derivatives as modulators of TNF activity
RU2737539C2 (ru) 2016-04-01 2020-12-01 Юсб Биофарма Спрл Способ очистки белка
EP3441065B1 (fr) 2016-04-06 2024-10-09 Astellas Pharma Inc. Moulage tridimensionnel à élution rapide, filament pour moulage tridimensionnel à élution rapide et matériau pour moulage tridimensionnel à élution rapide
US10485857B2 (en) 2016-04-07 2019-11-26 Boehringer Ingelheim Animal Health USA Inc. Heartworm vaccine, methods and uses thereof
CA3018352A1 (fr) 2016-04-13 2017-10-19 Ucb Biopharma Sprl Derives de tetrahydroisoquinoleine
WO2017180770A1 (fr) 2016-04-13 2017-10-19 Synthetic Genomics, Inc. Systèmes de réplicon d'artérivirus recombinant et utilisations correspondantes
EP3429634A1 (fr) 2016-04-15 2019-01-23 Cellectis Méthode de mise au point par génie génétique de lymphocytes t hypersensibles à un promédicament spécifique pour une immunothérapie par expression génique
JP7184751B2 (ja) 2016-04-15 2022-12-06 イミュネクスト インコーポレイテッド 抗ヒトｖｉｓｔａ抗体およびその使用
RU2740309C2 (ru) 2016-04-27 2021-01-13 Пфайзер Инк. Антитела против il-33, композиции, способы и их применение
KR20170122650A (ko) 2016-04-27 2017-11-06 사회복지법인 삼성생명공익재단 미숙아 뇌실내 출혈 치료를 위한 고효능 줄기세포 선별법
CA3022494A1 (fr) 2016-05-01 2017-11-09 Ucb Biopharma Sprl Domaine de liaison a une proteine porteuse serique, avec affinite genetiquement modifiee
CA3022769A1 (fr) 2016-05-10 2017-11-16 Ares Trading S.A. Procedes de modulation de profils de galactosylation de proteines de proteines recombinantes a l'aide de galactose peracetyle
GB201608323D0 (en) 2016-05-12 2016-06-29 Ucb Biopharma Sprl Pharmaceutical compositions
GB201608797D0 (en) 2016-05-19 2016-07-06 Ucb Biopharma Sprl Therapeutic use
US20190336552A1 (en) 2016-05-30 2019-11-07 Astellas Pharma Inc. Genetically engineered vaccinia viruses
TW201808987A (zh) 2016-06-08 2018-03-16 健生生物科技公司 Ｇｍ－ｃｓｆ變體及使用方法
GB201610044D0 (en) 2016-06-08 2016-07-20 Ucb Biopharma Sprl Antibodies
GB201610198D0 (en) 2016-06-10 2016-07-27 Ucb Biopharma Sprl Anti-ige antibodies
MX2019000536A (es) 2016-07-14 2019-04-01 Pfizer Nuevas pirimidinas carboxamidas como inhibidores de enzima vanina-1.
WO2018011768A1 (fr) 2016-07-15 2018-01-18 Janssen Vaccines And Prevention B.V. Méthodes et compositions permettant l'induction d'une immunité protectrice contre l'infection par le virus de marburg
CN109563074B (zh) 2016-07-19 2021-09-28 安斯泰来制药株式会社 哌嗪衍生物
WO2018022851A1 (fr) 2016-07-28 2018-02-01 Mitobridge, Inc. Méthode de traitement de lésions rénales aiguës.
MA45770A (fr) 2016-07-29 2019-06-05 Pfizer Peptides cycliques en tant qu'antagonistes du récepteur c5
EP3498835A4 (fr) 2016-08-10 2020-03-18 Astellas Pharma Inc. Procédé de détection de gène hybride cldn18-arhgap6 ou de gène hybride cldn18-arhgap26 du cancer du pancréas
SG11201901081XA (en) 2016-08-17 2019-03-28 Boehringer Ingelheim Int Process for the preparation of highly concentrated liquid formulations containing biomolecules
US20190292265A1 (en) 2016-08-19 2019-09-26 Janssen Biotech, Inc. Methods of Treating Crohn's Disease with an Anti-NKG2D Antibody
DK3510141T3 (da) 2016-09-12 2023-12-04 Ares Trading Sa Fremgangsmåder til modulering af fremstillingsprofiler af rekombinante proteiner
SI3512833T1 (sl) 2016-09-15 2020-11-30 Boehringer Ingelheim International Gmbh Heteroarilne karboksamidne spojine kot inhibitorji RIPK2
AU2017333367A1 (en) 2016-09-27 2019-04-04 Fresenius Kabi Deutschland Gmbh Liquid pharmaceutical composition
GB201616563D0 (en) 2016-09-29 2016-11-16 Ucb Biopharma Sprl Therapeutic agents
US10537590B2 (en) 2016-09-30 2020-01-21 Boehringer Ingelheim International Gmbh Cyclic dinucleotide compounds
KR101971323B1 (ko) 2016-10-17 2019-04-23 사회복지법인 삼성생명공익재단 면역질환 치료를 위한 고효능 줄기세포 선별방법
EP3525828B1 (fr) 2016-10-17 2024-12-25 Pfizer Inc. Anticorps anti-edb et conjugués anticorps-médicament
KR101971322B1 (ko) 2016-10-17 2019-04-23 사회복지법인 삼성생명공익재단 Ｓｏｃｓ의　발현　또는　활성　억제를　이용한　고효능 줄기세포 선별방법
GB201617924D0 (en) 2016-10-24 2016-12-07 Ucb Biopharma Sprl Proteins and users
JPWO2018079570A1 (ja) 2016-10-26 2019-09-19 アステラス製薬株式会社 安定な医薬組成物
KR101837449B1 (ko) 2016-10-28 2018-03-12 삼성전자주식회사 마이크로 니들 패치, 마이크로 니들을 제조하는 방법 및 장치
EP3532500A1 (fr) 2016-10-31 2019-09-04 Vectura Limited Composition de poudre inhalable comprenant un anticorps il -13
WO2018078162A1 (fr) 2016-10-31 2018-05-03 Ares Trading S.A. Composition pharmaceutique liquide
MY195529A (en) 2016-11-18 2023-01-30 Astellas Pharma Inc Novel Anti-Human MUC1 Antibody Fab Fragment
WO2018098213A1 (fr) 2016-11-23 2018-05-31 Wake Forest University Health Sciences Analyse d'image médicale à l'aide d'informations de déformation mécanique
GB201620948D0 (en) 2016-12-09 2017-01-25 Ucb Biopharma Sprl Therapeutic agents
MX392340B (es) 2016-12-13 2025-03-21 Astellas Pharma Inc Anticuerpo anti cd73 humana.
GB201621728D0 (en) 2016-12-20 2017-02-01 Ucb Biopharma Sprl Methods
US20200087390A1 (en) 2016-12-21 2020-03-19 Amgen Inc. Anti-tnf alpha antibody formulations
TWI754702B (zh) 2016-12-28 2022-02-11 德商Ｕｃｂ製藥有限公司 （氮雜）吲哚－和苯並呋喃－３－磺醯胺類
MX392525B (es) 2017-01-20 2025-03-12 Pfizer Composiciones inmunogenicas para su uso en vacunas neumococicas
PL3575284T3 (pl) 2017-01-24 2021-12-27 Astellas Pharma Inc. Związek prolinamidu podstawiony fenylodifluorometylem
WO2018138591A1 (fr) 2017-01-24 2018-08-02 Pfizer Inc. Dérivés de calichéamicine et conjugués anticorps-médicaments de ceux-ci
MX2019007053A (es) 2017-01-26 2019-08-29 Ucb Biopharma Sprl Derivados de bis-heteroarilo como moduladores de la agregacion de proteinas.
US10889584B2 (en) 2017-01-26 2021-01-12 UCB Biopharma SRL Bicyclic bis-heteroaryl derivatives as modulators of protein aggregation
JP2020506916A (ja) 2017-01-30 2020-03-05 ヤンセン バイオテツク，インコーポレーテツド 活動性乾癬性関節炎の治療のための抗ｔｎｆ抗体、組成物、及び方法
JOP20190186A1 (ar) 2017-02-02 2019-08-01 Astellas Pharma Inc مركب كينازولين
EP3579871A4 (fr) 2017-02-07 2021-07-21 Janssen Biotech, Inc. Anticorps anti-tnf, compositions et méthodes pour le traitement de la spondylarthrite ankylosante active
EP3582813A4 (fr) 2017-02-16 2020-12-30 XBiotech, Inc Traitement de l'hidradénite suppurative
WO2018150269A1 (fr) 2017-02-17 2018-08-23 Lonza Ltd. Cellules à intégration spécifique au site à sites multiples pour protéines difficiles à exprimer
EP4417262A3 (fr) 2017-03-01 2024-11-27 Janssen Sciences Ireland Unlimited Company Polythérapie
EP3372241A1 (fr) 2017-03-06 2018-09-12 Ares Trading S.A. Composition pharmaceutique liquide
EP3372242A1 (fr) 2017-03-06 2018-09-12 Ares Trading S.A. Composition pharmaceutique liquide
WO2018163030A1 (fr) 2017-03-10 2018-09-13 Pfizer Inc. Dérivés d'imidazo [4,5-c] quinoléine substitués cycliques
EP3596078B1 (fr) 2017-03-15 2023-04-12 UCB Biopharma SRL Dérivés d'imidazoles pentacycliques condensés en tant que modulateurs de l'activité de tnf
JP6901292B2 (ja) 2017-03-15 2021-07-14 株式会社Adeka 水溶性組成物、その硬化物の製造方法、およびその硬化物、並びにアシルホスフィン酸塩
US20200085944A1 (en) 2017-03-17 2020-03-19 Curevac Ag Rna vaccine and immune checkpoint inhibitors for combined anticancer therapy
JOP20190218A1 (ar) 2017-03-22 2019-09-22 Boehringer Ingelheim Int مركبات ثنائية النيوكليوتيدات حلقية معدلة
CA3053226A1 (fr) 2017-03-31 2018-10-04 Boehringer Ingelheim International Gmbh Polytherapie anticancereuse
PT3939980T (pt) 2017-04-25 2023-08-07 UCB Biopharma SRL Processo de preparação de derivados de imidazol pentacíclico fundido e utilizações dos mesmos como moduladores da atividade do tnf
EP3615687A4 (fr) 2017-04-26 2021-01-13 The RNA Medicines Company, Inc. Agents de liaison d'oligonucléotides
AU2018281045A1 (en) 2017-06-05 2019-12-12 Janssen Biotech, Inc. Engineered multispecific antibodies and other multimeric proteins with asymmetrical CH2-CH3 region mutations
MX394645B (es) 2017-06-12 2025-03-21 Boehringer Ingelheim Int Compuestos heteroaromáticos como inhibidores de vanina.
GB201709456D0 (en) 2017-06-14 2017-07-26 Ucb Biopharma Sprl Therapeutic agents
AU2018300189B2 (en) 2017-07-14 2025-05-15 Pfizer, Inc. Antibodies to MAdCAM
WO2019018647A1 (fr) 2017-07-20 2019-01-24 Pfizer Inc. Anticorps anti-gd3 et conjugués anticorps-médicament
US11560549B2 (en) 2017-08-11 2023-01-24 Boehringer Ingelheim International Gmbh Integration sites in CHO cells
WO2019035649A1 (fr) 2017-08-14 2019-02-21 주식회사 레고켐 바이오사이언스 Conjugués anticorps-médicament comprenant un anticorps contre egfrviii
EP3668858A1 (fr) 2017-08-14 2020-06-24 Pfizer Inc Pyrazolo[1,5-a]pyrazin-4-yl et dérivés associés
CN111094566B (zh) 2017-08-23 2024-05-24 诺华股份有限公司 多拷贝基因蛋白表达系统
CA3074317C (fr) 2017-08-25 2024-06-18 Janssen Biotech, Inc. Domaines de type iii de fibronectine liant fc.gamma.rii, leurs conjugues et molecules multispecifiques les comprenant
EP3676281A1 (fr) 2017-08-30 2020-07-08 Ares Trading S.A. Procédé de purification de protéines
AU2018325645C1 (en) 2017-08-31 2025-01-30 Hyogo College Of Medicine IL-33 antagonist-containing therapeutic agent for endometriosis
EP3681504B1 (fr) 2017-09-14 2023-08-23 Icagen, Inc. Procédés de détection utilisant la fluorescence x
TW201922780A (zh) 2017-09-25 2019-06-16 美商健生生物科技公司 以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法
WO2019059741A1 (fr) 2017-09-25 2019-03-28 사회복지법인 삼성생명공익재단 Forme posologique à base de cellules souches contenant du liquide céphalo-rachidien et son procédé de production
US11364303B2 (en) 2017-09-29 2022-06-21 Pfizer Inc. Cysteine engineered antibody drug conjugates
US11447559B2 (en) 2017-09-29 2022-09-20 Mogam Institute For Biomedical Research Anti-BCMA antibody having high affinity for BCMA and pharmaceutical composition for treatment of cancer, comprising same
US20190153096A1 (en) 2017-10-02 2019-05-23 Covagen Ag Cd3/cd33 bispecific binding molecules
US20190100587A1 (en) 2017-10-02 2019-04-04 Covagen Ag IgG1 Fc MUTANTS WITH ABLATED EFFECTOR FUNCTIONS
EP3694551A1 (fr) 2017-10-13 2020-08-19 Merck Patent GmbH Combinaison d'un inhibiteur de parp et d'un antagoniste de liaison d'axe pd-1
SG11202003354VA (en) 2017-10-13 2020-05-28 Boehringer Ingelheim Int Perfusion medium
CN111630069B (zh) 2017-10-13 2024-05-31 勃林格殷格翰国际有限公司 针对Thomsen-nouvelle(Tn)抗原的人抗体
MX2020004074A (es) 2017-10-19 2020-10-16 Debiopharm Int Sa Producto de combinacion para el tratamiento de cancer.
MX2020004381A (es) 2017-10-27 2020-08-20 Pfizer Anticuerpos y conjugados de anticuerpo-farmaco especificos para cd123 y usos de los mismos.
US20190135910A1 (en) 2017-11-06 2019-05-09 Janssen Biotech, Inc. Safe and Effective Method of Treating Psoriatic Arthritis with Anti-IL23 Specific Antibody
BR112020007884A2 (pt) 2017-11-20 2020-11-03 Janssen Pharmaceuticals, Inc. método de proporcionar uma administração segura de vetores adenovirais que codificam um antígeno de vírus zika
GB201719447D0 (en) 2017-11-23 2018-01-10 Ucb Biopharma Sprl Pharmaceutical composition
KR20190064293A (ko) 2017-11-30 2019-06-10 (주)메디노 미숙아 뇌실내 출혈 치료를 위한 고효능 줄기세포 선별법
BR112020010753A2 (pt) 2017-12-01 2020-11-24 The Regents Of The University Of California anticorpos anti-cxcr5 e composições e usos dos mesmos
GB201720970D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Antibodies
GB201720975D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Anti-alpha synuclein antibodies
TW201938165A (zh) 2017-12-18 2019-10-01 美商輝瑞股份有限公司 治療癌症的方法及組合療法
US11020476B2 (en) 2017-12-19 2021-06-01 Janssen Sciences Ireland Unlimited Company Methods and compositions for inducing an immune response against Hepatitis B Virus (HBV)
MX2020006471A (es) 2017-12-19 2020-09-22 Janssen Sciences Ireland Unlimited Co Metodos y composiciones para inducir una respuesta inmune contra el virus de hepatitis b (hbv).
CA3085405A1 (fr) 2017-12-20 2019-06-27 Ares Trading S.A. Procedes de modulation de profils de mannosylation de proteines a l'aide d'un ionophore de polyether
EP3727374A4 (fr) 2017-12-21 2021-11-10 Merck Patent GmbH Association d'un anticorps anti-pd-l1 et d'un inhibiteur de l'ido1 pour le traitement du cancer
KR20200110356A (ko) 2018-01-15 2020-09-23 화이자 인코포레이티드 키메라 항원 수용체 면역요법을 4-1bb 효능제와 조합하여 투여하는 방법
EP3740478B1 (fr) 2018-01-15 2023-11-01 UCB Biopharma SRL Dérivés d'imidazole fusionnés utilisés en tant qu'inhibiteurs d'il-17
TWI878213B (zh) 2018-02-01 2025-04-01 美商輝瑞大藥廠 對cd70具特異性抗體及其用途
TW201936633A (zh) 2018-02-01 2019-09-16 美商輝瑞大藥廠 標靶至cd70的嵌合抗原受體
CN111788222A (zh) 2018-02-27 2020-10-16 辉瑞大药厂 抗体纯化
WO2019166946A1 (fr) 2018-02-28 2019-09-06 Pfizer Inc. Variants d'il-15 et leurs utilisations
EP3759132A1 (fr) 2018-03-02 2021-01-06 Allogene Therapeutics, Inc. Récepteurs de cytokines chimériques inductibles
ES3064335T3 (en) 2018-03-05 2026-04-24 Janssen Biotech Inc Methods of treating crohn's disease with anti-il23 specific antibody
IL277095B2 (en) 2018-03-07 2025-10-01 Pfizer Preparations containing anti-PD-1 antibody
WO2019177883A2 (fr) 2018-03-14 2019-09-19 Boehringer Ingelheim International Gmbh Utilisation d'anticorps anti-il-36 r pour le traitement d'une maladie intestinale inflammatoire
AU2019236105B2 (en) 2018-03-14 2025-07-31 Boehringer Ingelheim International Gmbh Use of anti-IL-36R antibodies for treatment of generalized pustular psoriasis
US20210009627A1 (en) 2018-03-27 2021-01-14 Boehringer Ingelheim International Gmbh Cyclic dinucleotide compounds containing 2-aza-hypoxanthine or 6h-pytazolo[1,5-d][1,2,4]trizain-7-one as string agonists
JP2021519279A (ja) 2018-03-27 2021-08-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 修飾環式ジヌクレオチド化合物
HUE058711T2 (hu) 2018-04-20 2022-09-28 Janssen Biotech Inc Kromatográfiás oszlopos minõség-ellenõrzés anti-IL12/IL23 ellenanyag-készítmények elõállítására szolgáló gyártási eljárásokban
WO2019212253A1 (fr) 2018-05-02 2019-11-07 사회복지법인 삼성생명공익재단 Anticorps se liant de manière spécifique à c-met et utilisation associée
KR20210006412A (ko) 2018-05-08 2021-01-18 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 디히드로피리미딘 유도체 및 hbv 감염 또는 hbv-유도성 질환의 치료에 있어서의 이의 용도
JP2021523138A (ja) 2018-05-11 2021-09-02 ヤンセン バイオテツク，インコーポレーテツド Ｉｌ−２３抗体を使用してうつを治療する方法
SG11202011306TA (en) 2018-05-16 2020-12-30 Janssen Biotech Inc Bcma/cd3 and gprdc5d/cd3 bispecific antibodies for use in cancer therapy
US11578124B2 (en) 2018-05-18 2023-02-14 Janssen Biotech, Inc. Safe and effective method of treating lupus with anti-IL12/IL23 antibody
EP3569618A1 (fr) 2018-05-19 2019-11-20 Boehringer Ingelheim International GmbH Antagonisation d'anticorps cd73
DK3797121T3 (da) 2018-05-23 2024-07-08 Pfizer Antistoffer, der er specifikke for CD3, og anvendelser deraf
BR112020022595A2 (pt) 2018-05-23 2021-02-09 Pfizer Inc. anticorpos específicos para gucy2c e usos dos mesmos
CN112912397B (zh) 2018-05-24 2025-03-14 詹森生物科技公司 抗cd3抗体及其用途
MA52777A (fr) 2018-05-24 2021-04-14 Janssen Biotech Inc Agents de liaison psma et utilisations correspondantes
EP3802846A1 (fr) 2018-05-24 2021-04-14 Ares Trading S.A. Procédé de régulation du degré d'afucosylation d'une composition de glycoprotéines
JOP20190116A1 (ar) 2018-05-24 2019-11-24 Janssen Biotech Inc الأجسام المضادة لتكتل التمايز 33 (cd33)، والأجسام المضادة ثنائية النوعية لتكتل التمايز 33 (cd33)/تكتل التمايز 3 (cd3) واستخداماتها
WO2019231243A1 (fr) 2018-05-29 2019-12-05 사회복지법인 삼성생명공익재단 Cellule nourricière exprimant ox40l et procédé de culture de cellules tueuses naturelles l'utilisant
US20190365743A1 (en) 2018-05-30 2019-12-05 Hedgepath Pharmaceuticals, Inc. Hedgehog pathway inhibition for treatment of high-risk basal cell carcinoma or high-risk basal cell carcinoma nevus syndrome
WO2019235839A1 (fr) 2018-06-05 2019-12-12 사회복지법인 삼성생명공익재단 Modèle animal de phénotype d'ophtalmopathie de graves, son procédé d'élaboration et procédé de recherche par criblage d'une substance thérapeutique contre l'ophtalmopathie de graves
US20210196823A1 (en) 2018-06-08 2021-07-01 Pfizer Inc. Methods of Treating Metabolic Disease
TWI848953B (zh) 2018-06-09 2024-07-21 德商百靈佳殷格翰國際股份有限公司 針對癌症治療之多特異性結合蛋白
CN119185533A (zh) 2018-06-11 2024-12-27 耶鲁大学 新型免疫检查点抑制剂
GB201809700D0 (en) 2018-06-13 2018-08-01 Singapore Health Serv Pte Ltd IL-11 antibodies
GB201809699D0 (en) 2018-06-13 2018-08-01 Singapore Health Serv Pte Ltd IL-11 antibodies
EA202092962A1 (ru) 2018-06-18 2021-09-06 Янссен Фармацевтика Нв Производные пиразола в качестве ингибиторов malt1
JP7296408B2 (ja) 2018-06-18 2023-06-22 ヤンセン ファーマシューティカ エヌ．ベー． Ｍａｌｔ１阻害剤としてのピラゾール誘導体
CA3099605A1 (fr) 2018-06-26 2020-01-02 Janssen Sciences Ireland Unlimited Company Derives de dihydropyrimidine et leurs utilisations dans le traitement d'une infection par le virus de l'hepatite b ou de maladies induites par le virus de l'hepatite b
KR20210032972A (ko) 2018-06-27 2021-03-25 베링거 인겔하임 에르체파우 게엠베하 운트 코 카게 전사인자를 사용하여 단백질 발현을 증가시키는 수단 및 방법
AU2019291890A1 (en) 2018-06-29 2020-12-17 Boehringer Ingelheim International Gmbh Anti-CD40 antibodies for use in treating autoimmune disease
JP7634474B2 (ja) 2018-07-18 2025-02-21 ヤンセン バイオテツク，インコーポレーテツド 抗ｉｌ２３特異的抗体で治療した後の持続応答予測因子
US11053235B2 (en) 2018-08-09 2021-07-06 Janssen Sciences Ireland Unlimited Company Substituted 1,4-dihydropyrimidines for the treatment of HBV infection or HBV-induced diseases
CA3109905A1 (fr) 2018-08-20 2020-02-27 Pfizer Inc. Anticorps anti-gdf15, compositions et procedes d'utilisation
US20200061015A1 (en) 2018-08-23 2020-02-27 Janssen Biotech, Inc. Lipase Degradation Resistant Surfactants for Use in Large Molecule Therapeutic Formulations
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
DK3844161T3 (da) 2018-08-28 2022-12-12 Boehringer Ingelheim Int Heteroaromatiske forbindelser som vanininhibitorer.
CN112654637A (zh) 2018-09-05 2021-04-13 株式会社Lg化学 包含可被o-糖基化的多肽区的融合多肽
US11359024B2 (en) 2018-09-07 2022-06-14 Pfizer Inc. Anti-AVB8 antibodies and compositions and uses thereof

Also Published As

Publication number Publication date
EP3824906A1 (fr) 2021-05-26
WO2018119142A1 (fr) 2018-06-28
US12247071B2 (en) 2025-03-11
US20200087390A1 (en) 2020-03-19
US20230151086A1 (en) 2023-05-18
EP4467565A3 (fr) 2025-03-12
US20250171527A1 (en) 2025-05-29
EP3558363A1 (fr) 2019-10-30
EP4467565A2 (fr) 2024-11-27

Similar Documents

Publication Publication Date Title
MA49043A (fr) Formulation stable d'anticorps
EP3618871A4 (fr) Formulations d'anticorps anti-lag3 etco-formulations d'anticorps anti-lag3 et d'anticorps anti-pd-1
MA52884A (fr) Anticorps anti-il-11
MA53434A (fr) Anticorps anti-tigit
EP3484518A4 (fr) Conjugués d'adjuvant d'anticorps
MA56006A (fr) Formulations sous-cutanées d'anticorps her2
EP3359573A4 (fr) Marquage d'anticorps
MA46525A (fr) Anticorps anti-lag-3 et compositions
MA49034A (fr) Anticorps anti-lag3
MA47694A (fr) Anticorps anti-tigit
MA44659A (fr) Anticorps anti-tim-3 et compositions
MA49726A (fr) Formulation d'anticorps anti-cgrp
EP3883970A4 (fr) Anticorps anti-b7-h3
MA47268A (fr) Anticorps anti-gpc3
MA44236A (fr) Anticorps anti-tgfbêta 2
EP3430731A4 (fr) Architecture d'iugw
MA44381A (fr) Format d'anticorps hétérodimères multispécifiques
MA49749A (fr) Anticorps anti-cd137
EP3496753A4 (fr) Formulation d'anticorps anti-pd-1
MA44054A (fr) Plateforme d'anticorps bispécifique
EP2968553A4 (fr) Formulations d'anticorps
MA54052A (fr) Formulation d'anticorps
EP3823978A4 (fr) Compositions d'anticorps anti-fcrn
MA51903A (fr) Formulations d'anticorps b7-h4
MA52152A (fr) Anticorps